Rational drug design of 6-substituted 4-anilino-2-phenylpyrimidines for exploration of novel ABCG2 binding site
作者:Katja Silbermann、Jiyang Li、Vigneshwaran Namasivayam、Sven Marcel Stefan、Michael Wiese
DOI:10.1016/j.ejmech.2020.113045
日期:2021.2
SN-38 but also a negative influence on cell viability in general. Nevertheless, several candidates have EC50 values in the low double-digit nanomolar concentration range, qualifying them as some of the most potent reversers of ABCG2-mediated MDR. In addition, five novel multitarget ABCB1/ABCC1/ABCG2 inhibitors were discovered, four of them exerting their inhibitory power against the three stated transporters
在寻找新颖,高效且无毒的辅助化学疗法以解决ABC转运蛋白介导的多药耐药性(MDR)的主要问题时,发现嘧啶是现代ABCG2抑制剂的有前途的化合物类别。由于ABCG2介导的MDR是白血病,胰腺癌和乳腺癌化学疗法的主要障碍,因此,对于未来的临床肿瘤学,非常需要辅助化学疗法。最近,报道了对最有效的ABCG2介导的MDR逆转剂之一的对接研究,揭示了ABCG2的第二个潜在结合口袋。基于这个(子)口袋,合成了16种不同的6个取代的4-苯胺基-2-苯基嘧啶系列,以探索这些ABCG2抑制剂抑制活性的潜在增加。评估了这些化合物对ABCG2介导的脱镁叶绿酸A转运以及ABCB1和ABCC1介导的钙黄绿素AM的影响。另外在MDR逆转分析中对它们进行了评估,以确定其半最大逆转浓度(EC50)。6取代不仅与SN-38结合使用,对ABCG2过表达细胞的毒性增加,而且总体上对细胞活力也有负面影响。尽管如此,仍有几位候选者的EC